The analysis of the current state of quality management tools implementation in clinical trials of drugs in Ukraine
DOI:
https://doi.org/10.24959/cphj.20.1517Keywords:
clinical trial quality management system, quality management system, quality management tools, clinical trialsclinical trial quality management system, clinical trialsAbstract
The specificity of the processes of organizing and conducting clinical trials (CT) determines the particular requirements for quality management systems (QMS) and their improvement. That is why there is a constant need to assess the effectiveness of CT quality management and determine the need to develop new QMS optimization tools that have been already implemented in the work.
Аim. To study the state of the implementation of quality management tools in CT of drugs and assess their use in practice.
Materials and methods. To identify problems and determine the need to create the ways to improve CT QMS we conducted a survey of 217 Ukrainian specialists working in the field of organizing and conducting CT.
Results. According to the respondents, the most used QT quality management tools to ensure the proper level of quality in organizing and conducting CT are monitoring / audit, and routine internal quality control. The assessment of the knowledge level about risk-based quality management tools has shown that the personnel carrying out the processes of organizing and conducting CT does not fully possess even basic knowledge about the proper use of CT quality management tools. The analysis of the QMS implementation in the practical work of the respondents’ organizations has shown an insufficient level of implementation of such systems and their certification.
Conclusions. Thus, it is advisable to perform work on the development of methods for the active implementation of risk-based tools into practice; it is necessary to train specialists in the field of CT according to the specialized professional and educational programs, as well as to use the wider implementation of QMS in organizations and their certification.
References
Zupanets, K. O., Dobrova, V. Ye., Proskurnia, O. M. (2015). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 4(42), 60–66.
Zupanets, K. O., Dobrova, V. Ye. (2015). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 6(44), 49 – 57.
3. Guideline for Good Clinical Practice. ICH Harmonised Guideline Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). (2015). International Conference оn Harmonisation оf Technical Requirements for Registration оf Pharmaceuticals for Human Use. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Addendum_Step2.pdf
4. ISO 9001:2015 Quality management systems — Requirements. (2015). ISO, 40.
Suprin, M., Chow, A., Pillwein, M., Rowe, J., Ryan, M., Rygiel-Zbikowska, B., … Tomlin, I.(2019). Quality Risk Management Framework: Guidance for Successful Implementation of Risk Management in Clinical Development. Therapeutic Innovation & Regulatory Science, 53(1), 36–44. https://doi.org/10.1177/2168479018817752
Tantsyura, V., Dunn, I. M., Fendt, K., Kim, Y. J., Waters, J., & Mitchel, J. (2015). Risk-Based Monitoring. Therapeutic Innovation & Regulatory Science, 49(6), 903–910. https://doi.org/10.1177/2168479015586001
Callery-D’Amico, S., Sam, L. M., Grey, T. H., & Greenwood, D. J. (2016). TransCelerate’s Clinical Quality Management System. Therapeutic Innovation & Regulatory Science, 50(5), 530–535. https://doi.org/10.1177/2168479016657129
Meeker-O’Connell, A., Borda, M. M., Little, J. A., & Sam, L. M. (2015). Enhancing Quality and Efficiency in Clinical Development Through a Clinical QMS Conceptual Framework. Therapeutic Innovation & Regulatory Science, 49(5), 615–622. https://doi.org/10.1177/2168479015596018
Zupanets, К. О., Dobrova, V. Ye. (2016). Process model of the trial site quality management system. Asian Journal of Pharmaceutical and Clinical Research, 9 (3), 225–228.
Zupanets, E. A., & Dobrova, V. Y. (2016). The analysis of specialists’ opinion on the implementation of concept of risk management in clinical trials of drugs. Zaporozhye Medical Journal, 3. https://doi.org/10.14739/2310-1210.2016.3.77004
Vereshak, V., Dobrova, V., Proskurnia, O. (2018). Management system improvement of the research centres by FMEA implementation. Management and entrepreneurship: trends of development, 4(6), 8–19. https://doi.org/10.26661/2522-1566/2018-4/06-01
ICH Q9 «Risk management». (n.d.). Available at: http://www.gmpua.com/World/Ukraine/nastanova42422011.pdf
ICH Q10 «Pharmaceutical quality system». (n.d.). Available at: http://www.gmpua.com/World/Ukraine/nastanova42432011.pdf
Zupanets, I. A., Dobrova, V. Ie., Popov, O. S., Kozyrieva, O. M., Sumets, O. M. (2019). Materialy dopovidei VIII naukovo-praktychnoi konferentsii z mizhnarodnoiu uchastiu (01.11.2019). Kharkiv: Monohraf, 320–322.
Dobrova, V. Y., Ratushna, K. L. (2019). ISO 9001:2015 AND updated guideline for good clinical practice: considerations for synergic application. Zbirnyk materialiv XIII naukovo-praktychnoi konferentsii “Upravlinnia yakistiu v farmatsii” (17.05.2019), 47.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
